| Description | DGAT2 Human Pre-designed siRNA Set A contains three designed siRNAs for DGAT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DGAT2 siRNA-1: 5 nmol (HPLC) DGAT2 siRNA-2: 5 nmol (HPLC) DGAT2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:DGAT2 Human Pre-designed siRNA Set A contains three designed siRNAs for DGAT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DGAT2 siRNA-1: 5 nmol (HPLC) DGAT2 siRNA-2: 5 nmol (HPLC) DGAT2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Product IntroductionKGF keratinocyte growth factor (KGF), a cytokine identified by Rubin et al (1989) from the culture supernatant of embryonic lung fibroblasts, is an FGF family member, namely FGF-7.KGF is secreted by stromal cells and its receptor is distributed in epithelial cells, where it is a Product IntroductionKGF keratinocyte growth factor (KGF), a cytokine identified by Rubin et al (1989) from the culture supernatant of embryonic lung fibroblasts, is an FGF family member, namely FGF-7.KGF is secreted by stromal cells and its receptor is distributed in epithelial cells, where it is a potent epithelial cell specific growth factor, and its mitogenic activity is mainly expressed in keratinocytes, which can specifically promote epithelial cell proliferation, migration and differentiation, and is closely related to many aspects, such as organ development, wound repair, tumorigenesis and immune reconstitution.Osrhkgf was created using genetic recombination, expressed from rice endosperm cells and through a protein purification process.Specification parametersSource Oryza sativaAppearance white lyophilized powderActivity ≥1.0×105IU/mgpH 6.5-7.5Molecular weight 19.0 kDEndotoxin ≦0.1EU/ugCAS No 148348-15-6Matters needing attentionReconstitution: it is recommended to lyophilize the powder of osrhkgf to 100-200 UG/ml with sterile water to make further dilutions with other solvents.The dissolved osrhkgf could be stored for 2-7 days at 4 ◦ C and used up as soon as possible.To not use for short periods, store at - 20 ℃.Use as soon as possible after opening to avoid contamination.Limitations of useIt is suitable for research, laboratory and production use only and cannot be used directly in humans... Read More | Purity≥ 92% SDS-PAGEActual molecular weight 15&17kDaFunctionChemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like Purity≥ 92% SDS-PAGEActual molecular weight 15&17kDaFunctionChemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis... Read More | Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases... Read More |